

Merrion Pharmaceuticals plc

09 April 2009

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

The Company was advised on 9 April 2009 that on that date, Michael McKenna, a Director of the Company, sold 80,000 ordinary shares in the Company at a price of €3.50 per share, representing 0.47% of the Company's issued share capital. Following this sale, Michael McKenna has a total interest of 694,198 shares in the Company representing 4.1% of the Company's issued share capital. The proceeds from the sale will be used to meet US personal tax liabilities arising on the issuance of the shares to Michael McKenna.

The Company was advised on 9 April 2009 that on that date, Tom Leonard, Chief Scientific Officer of the Company, sold 42,000 ordinary shares in the Company at a price of €3.50 per share, representing 0.25% of the Company's issued share capital. Following this sale, Tom Leonard has a total interest of 404,504 shares in the Company representing 2.4% of the Company's issued share capital. The proceeds from the sale will be used to meet US personal tax liabilities arising on the issuance of the shares to Tom Leonard.

The Company was advised on 9 April 2009 that on that date, the Estate of Dr Anthony Ryan (Decd) and Declan Ryan, connected parties of the Company, sold 307,447 and 307,446 ordinary shares in the Company, respectively, at a price of €3.50 per share, each representing 1.82% of the Company's issued share capital. Following this sale, the Estate of Dr Anthony Ryan (Decd) has a total interest of 1,245,319 shares in the Company representing 7.36% of the Company's issued share capital and Declan Ryan has a total interest of 2,462,966 shares in the Company representing 14.55% of the Company's issued share capital.

Enquiries:

Goodbody Corporate Finance
Finbarr Griffin
Diane Hodgson
+353 1 667 0400

Merrion Pharmaceuticals plc
Jonathan O'Connell
+353 1 672 9272

Media enquiries
Young Communications
Wally Young
+353 (0)1 668 0530
+353 (0) 87 247 1520
youngcom@eircom.net

For further information: www.merrionpharma.com